{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:58:14Z","timestamp":1783090694837,"version":"3.54.6"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,11]]},"DOI":"10.7759\/cureus.106841","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:53:41Z","timestamp":1775912021000},"source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Efficacy and Safety of Botulinum Toxin Type A in Erythematotelangiectatic Rosacea: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Khadija","family":"Marrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Althiyabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alsannaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renad","family":"Alfalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumanah","family":"Soroje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyad","family":"Anbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtiahl","family":"Al Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameen","family":"Al Awadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether L","year":"2018","unstructured":"Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018, 179:282-9. 10.1111\/bjd.16481","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S307013","article-title":"Use of botulinum toxin in treating rosacea: a systematic review","volume":"14","author":"Zhang H","year":"2021","unstructured":"Zhang H, Tang K, Wang Y, Fang R, Sun Q. Use of botulinum toxin in treating rosacea: a systematic review. Clin Cosmet Investig Dermatol. 2021, 14:407-17. 10.2147\/CCID.S307013","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-018-0699-4","article-title":"Registration of systematic reviews in PROSPERO: 30,000 records and counting","volume":"7","author":"Page MJ","year":"2018","unstructured":"Page MJ, Shamseer L, Tricco AC. Registration of systematic reviews in PROSPERO: 30,000 records and counting. Syst Rev. 2018, 7:32. 10.1186\/s13643-018-0699-4","journal-title":"Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami M","year":"2020","unstructured":"Amir-Behghadami M, Janati A. Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020, 37:387. 10.1136\/emermed-2020-209567","journal-title":"Emerg Med J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001819","article-title":"Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema","volume":"45","author":"Kim MJ","year":"2019","unstructured":"Kim MJ, Kim JH, Cheon HI, et al.. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019, 45:1155-62. 10.1097\/DSS.0000000000001819","journal-title":"Dermatol Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004528","article-title":"Effects of botulinum toxin type A treatment on clinical and biophysical parameters in patients with erythematotelangiectatic rosacea: a prospective, randomized, controlled, double-blind study","volume":"51","author":"Da\u011fta\u015f BB","year":"2025","unstructured":"Da\u011fta\u015f BB, Erdem O, G\u00fcne\u00e7 T\u0130, Avc\u0131 EB, Manav V, Koku Aksu AE. Effects of botulinum toxin type A treatment on clinical and biophysical parameters in patients with erythematotelangiectatic rosacea: a prospective, randomized, controlled, double-blind study. Dermatol Surg. 2025, 51:515-21. 10.1097\/DSS.0000000000004528","journal-title":"Dermatol Surg"},{"key":"ref10","article-title":"A pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea","volume":"16","author":"Dayan SH","year":"2017","unstructured":"Dayan SH, Ashourian N, Cho K. A pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea. J Drugs Dermatol. 2017, 16:549-54.","journal-title":"J Drugs Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000277","article-title":"Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea","volume":"41 Suppl 1","author":"Bloom BS","year":"2015","unstructured":"Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015, 41 Suppl 1:S9-16. 10.1097\/DSS.0000000000000277","journal-title":"Dermatol Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_274_2024","article-title":"Intradermal injection of botulinum toxin for erythema in rosacea: a scoping review and meta-analysis","volume":"91","author":"Yeh MC","year":"2025","unstructured":"Yeh MC, Shih YC, Huang YC. Intradermal injection of botulinum toxin for erythema in rosacea: a scoping review and meta-analysis. Indian J Dermatol Venereol Leprol. 2025, 91:448-54. 10.25259\/IJDVL_274_2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00784-0","article-title":"Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea","volume":"12","author":"Yang R","year":"2022","unstructured":"Yang R, Liu C, Liu W, Luo J, Cheng S, Mu X. Botulinum toxin A alleviates persistent erythema and flushing in patients with erythema telangiectasia rosacea. Dermatol Ther (Heidelb). 2022, 12:2285-94. 10.1007\/s13555-022-00784-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5021\/ad.24.171","article-title":"The anti-angiogenic effect of microbotox on rosacea is due to the suppressed secretion of VEGF by mast cells resulting from internalization of the MRGPRX2 receptor","volume":"37","author":"Wan J","year":"2025","unstructured":"Wan J, Le Y, Geng MM, Dong BQ, Liao ZK, Liu LX, Lei TC. The anti-angiogenic effect of microbotox on rosacea is due to the suppressed secretion of VEGF by mast cells resulting from internalization of the MRGPRX2 receptor. Ann Dermatol. 2025, 37:228-40. 10.5021\/ad.24.171","journal-title":"Ann Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450254-therapeutic-efficacy-and-safety-of-botulinum-toxin-type-a-in-erythematotelangiectatic-rosacea-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:53:42Z","timestamp":1775912022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450254-therapeutic-efficacy-and-safety-of-botulinum-toxin-type-a-in-erythematotelangiectatic-rosacea-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.106841","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,11]]}}}